CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2018—Natera announced a research collaboration with the Institut Jules Bordet, in Brussels, using the company’s Signatera research-use-only circulating tumor DNA assay to evaluate molecular response and minimal residual disease in women with early stage breast cancer.
Natera will analyze approximately 300 plasma specimens prospectively collected and banked from 80 patients diagnosed with nonmetastatic breast cancer who received neoadjuvant chemotherapy followed by surgery and who were then monitored for recurrence with serial imaging. The study will correlate results of the Signatera assay with clinical outcomes, including pathological response and event-free survival. The study is led by Michail Ignatiadis, MD, PhD, attending physician in the medical oncology department of Institut Jules Bordet and assistant professor, Université Libre de
Bruxelles.